期刊
CLINICAL CHEMISTRY
卷 56, 期 12, 页码 1804-1813出版社
OXFORD UNIV PRESS INC
DOI: 10.1373/clinchem.2010.152264
关键词
-
资金
- Waters, Inc.
- Bruker Daltonics, Inc.
- Nutrition and Obesity Research Center [NIH P30DK035816]
- Diabetes and Endocrinology Research Center [NIH P30DK017047]
- Clinical Mass Spectrometry Facility at the University of Washington
BACKGROUND: If liquid-chromatography-multiple-reaction-monitoring mass spectrometry (LC-MRM/MS) could be used in the large-scale preclinical verification of putative biomarkers, it would obviate the need for the development of expensive immunoassays. In addition, the translation of novel biomarkers to clinical use would be accelerated if the assays used in preclinical studies were the same as those used in the clinical laboratory. To validate this approach, we developed amultiplexed assay for the quantification of 2 clinically well-known biomarkers in human plasma, apolipoprotein A-I and apolipoprotein B (apoA-I and apoB). METHODS: We used Peptide Atlas to identify candidate peptides. Human samples were denatured with urea or trifluoroethanol, reduced and alkylated, and digested with trypsin. We compared reversed-phase chromatographic separation of peptides with normal flow and microflow, and we normalized endogenous peptide peak areas to internal standard peptides. We evaluated different methods of calibration and compared the final method with a nephelometric immunoassay. RESULTS: We developed a final method using trifluoroethanol denaturation, 21-h digestion, normal flow chromatography-electrospray ionization, and calibration with a single normal human plasma sample. For samples injected in duplicate, the method had intraassay CVs <6% and interassay CVs <12% for both proteins, and compared well with immunoassay (n = 47; Deming regression, LC-MRM/MS = 1.17 x immunoassay - 36.6; S-x ' y = 10.3 for apoA-I and LC-MRM/MS = 1.21 x immunoassay + 7.0; S-x ' y = 7.9 for apoB). CONCLUSIONS: Multiplexed quantification of proteins in human plasma/serum by LC-MRM/MS is possible and compares well with clinically useful immunoassays. The potential application of single-point calibration to large clinical studies could simplify efforts to reduce day-to-day digestion variability. (C) 2010 American Association for Clinical Chemistry
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据